Endometrial cancer drug cuts progression or death risk 41%

FDA grants Priority Review to following improved survival versus chemotherapy in phase 3 trial.

1

In the phase 3 TroFuse-005 trial, 776 patients with advanced or recurrent endometrial cancer received sacituzumab tirumotecan or physician’s choice of doxorubicin or paclitaxel.
2

At a median follow-up of 14 months, median overall survival was 19 months with sacituzumab tirumotecan and 12.1 months with chemotherapy, a 32% lower risk of death.
3

Median progression-free survival was 7.2 months with sacituzumab tirumotecan and 3.9 months with chemotherapy, a 41% lower risk of progression or death.
4

Objective response rates were 35.1% with sacituzumab tirumotecan and 17.3% with chemotherapy; median response duration was 11.1 and 6.9 months, respectively.
5

Grade 3 or higher treatment-related adverse events occurred in 54.4% of sacituzumab tirumotecan recipients and 41.4% of chemotherapy recipients; the drug remains investigational.

1